For the first time, an Alzheimers drug has shown to modify the disease rather than alleviate it.
A group of patients who took part in tests involving experimental drug ‘solanezumab’ showed reduced mental decline by 34%.
Patients with mild Alzheimers who started the treatment early experienced effects over three and a half years.
The results took place at Alzheimers Association International Conference in Washington D.C.
After years of no new treatments and failed trials, today’s findings offer some hope to those suffering the disease.